Abstracts tagged "Disease Activity"

Abstract Number: 2781 • 2017 ACR/ARHP Annual Meeting
Assessing RA Disease Activity with Promis Measures Using Smartphone Technology
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health information technology has enabled efficient measurement of PROs using Computer Adaptive Testing (CAT) methods, which have been shown to minimize missing data and…
Abstract Number: 432 • 2017 ACR/ARHP Annual Meeting
ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Janet E. Pope¹, Emmanouil Rampakakis², Mohammad Movahedi³, Angela Cesta³, John S. Sampalis⁴ and Claire Bombardier³, ¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada
ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data From a Rheumatoid Arthritis CohortBackground/Purpose: Positive serology for anti-citrullinated protein antibody…
Abstract Number: 870 • 2017 ACR/ARHP Annual Meeting
Detection of Left Ventricular Regional Function in Rheumatoid Arthritis Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Isamu Yokoe³, Akiyuki Kotoku⁴, Atsuma Nishiwaki⁵, Kaita Sugiyama⁶, Noboru Kitamura⁵ and Masami Takei⁵, ¹Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Kyoundo Hospital, Sasaki Institute, Tokyo, Japan, ⁴Advanced Biomedical Imaging Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Cardiac involvements cause of morbidity and mortality globally in rheumatoid arthritis (RA). Myocardial disease is typically clinically silent, only manifesting as myocardial dysfunction after…
Abstract Number: 1348 • 2017 ACR/ARHP Annual Meeting
Swollen Joint Count, but Not Inflammatory Cytokines, Differs By Frequency of Fish Consumption in a Cross-Sectional Rheumatoid Arthritis Cohort
Sara K. Tedeschi¹, Joan Bathon², Jon T. Giles³, Tzu-Chieh Lin⁴, Kazuki Yoshida⁵ and Daniel Solomon¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Omega-3 fatty acids downregulate pro-inflammatory cytokines, thus have been of interest as adjunctive rheumatoid arthritis (RA) therapy for decades. We previously reported an inverse…
Abstract Number: 1613 • 2017 ACR/ARHP Annual Meeting
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers
Noelle M. Teske¹, Khor Jia Ker^2,3, Rui Feng⁴, Benjamin F. Chong¹ and Victoria P Werth⁵, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Dermatology, National Skin Centre, Singapore, Singapore, ³Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: The natural disease course of patients with cutaneous lupus erythematosus (CLE) on standard-of-care treatments is not fully characterized. We sought to characterize their disease…
Abstract Number: 1972 • 2017 ACR/ARHP Annual Meeting
Causes of Death in 350 Patients with Systemic Autoimmune Rheumatic Diseases
Juan Gabriel Ovalles-Bonilla^1,2, Olaia Fernández-Berrizbeitia³, Julia Martínez-Barrio¹, Larissa Valor¹, Diana Hernández¹, Iustina Janta¹, Belen Serrano¹, Claudia Saez¹, Roberto Gonzalez¹, María Correyero¹, Leticia García¹, Ana López-Cerón¹, Alicia Silva¹, Juan Carlos Nieto¹, Carlos González^1,4, Indalecio Monteagudo¹ and Francisco Javier López Longo^1,4, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ⁴Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The major SARD have an increased mortality compared to the general population. It is well known that the main causes of death in Systemic…
Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting
Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)
Arthur Kavanaugh¹, Ronald F van Vollenhoven², Prashanth Sunkureddi³, Ying Zhang⁴, Jessica L. Suboticki⁵ and Josef S. Smolen⁶, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³University of Texas Medical Branch, Galveston, TX, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Mettawa, IL, ⁶Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…
Abstract Number: 2820 • 2017 ACR/ARHP Annual Meeting
Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments
Teresa Aberle¹, Rufei Lu², Sarah Cioli³, Stan Kamp¹, Wade DeJager¹, Stephen Apel⁴, Cristina Arriens⁵, Eliza Chakravarty⁶, Aikaterini Thanou¹, Joel M. Guthridge⁷, Joan T. Merrill⁸ and Judith A. James⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Oklahoma Medical research af, Edmond, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus patients commonly report sleep dysfunction, which is associated with upregulation of inflammatory cytokines in healthy people. Studies exploring relationships between self-reported sleep dysfunction…
Abstract Number: 435 • 2017 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes
Christine Iannaccone¹, Michelle Frits², Taysir G. Mahmoud³, Gabriela Maica⁴, Jonathan Coblyn⁵, Michael Weinblatt² and Nancy A. Shadick⁶, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: It is common for RA patients to interrupt their DMARD use due to events like infection, surgery, or pregnancy. Many RA patients may need…
Abstract Number: 921 • 2017 ACR/ARHP Annual Meeting
Discordant Patient-Physician Assessments of Disease Activity and Its Persistence Adversely Impact Quality of Life and Work Productivity in United States Hispanics with Rheumatoid Arthritis
George Karpouzas¹, Sera Ramadan², Chelsie Cost³, Taylor Draper⁴, Elizabeth Hernandez³ and Sarah Ormseth³, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Internal Medicine, Dignity Health St. Mary Medical Center, Long Beach, CA, ³Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Psychology, Loma Linda University, Loma Linda, CA
Background/Purpose: The impact of discordant patient-physician assessments of rheumatoid arthritis (RA) activity on quality of life is largely unknown. We examined the prevalence and stability…
Abstract Number: 1358 • 2017 ACR/ARHP Annual Meeting
Relationship between Serum Protein Pattern and High Disease Activity in Patients with Rheumatoid Arthritis
Pavel Horak¹, Anna Petráčková², Martina Skácelová³, Eva Kriegová⁴, Petra Schneiderová⁵ and František Mrázek⁵, ¹III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ²Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ³III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ⁴Department of Immunology,, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁵Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects joints. There is still limited information of serum biomarkers suitable for effective monitoring…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 1992 • 2017 ACR/ARHP Annual Meeting
Changes in Clinical Disease Activity Are Associated with Changes in the Total MRI Inflammation Score in Rheumatoid Arthritis Patients Who Are Escalating Therapy in a Treat-to-Target (T2T) Regimen
Fiona M. McQueen¹, Peter T. Chapman², Terina Pollock³, Dena D'Souza⁴, Arier Lee⁵, Nicola Dalbeth⁶, Lisa K. Stamp⁷, Karen Lindsay⁸ and Anthony Doyle^3,9, ¹Molecular Medicine, Univ of Auckland Sch of Med, Auckland, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Rheumatology, University of Auckland, Auckland, New Zealand, ⁵Biostatistics and Epidemiology, University of Auckland, Auckland, New Zealand, ⁶University of Auckland, Auckland, New Zealand, ⁷University of Otago, Christchurch, New Zealand, ⁸Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁹Anatomy with Radiology, University of Auckland, Auckland, New Zealand
Background/Purpose: RA patients are managed using treat-to target (T2T) regimens often utilizing the DAS28CRP as an outcome measure. In this study we compared clinical changes…
Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Hiroki Wakabayashi¹, Hitoshi Inada², Yosuke Nishioka³, Masahiro Hasegawa^1,4, Kusuki Nishioka⁵ and Akihiro Sudo⁶, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ²Orthopaedic Surgery, Suzuka General Hospital, Suzuka, Japan, ³Clinical Research Institute for Rheumatic Disease, Shima, Japan, ⁴Mie University Graduate School of Medicine, Tsu, Japan, ⁵Tokyo Medical University, Shinjuku, Japan, ⁶Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…
Abstract Number: 2834 • 2017 ACR/ARHP Annual Meeting
Healthcare Cost Drivers in Rheumatoid Arthritis
Nina Mars¹, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³University of Helsinki, Helsinki, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare resource utilization, but knowledge about factors determining healthcare costs is limited. The aim was to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].